{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:56:52Z","timestamp":1792432612436,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jtho.2024.07.009","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:03:58Z","timestamp":1721088238000},"page":"1539-1549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6759-9351","authenticated-orcid":false,"given":"Kaushal","family":"Parikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Dimou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Leventakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Shanshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huamao M.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana R.","family":"Bonta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.07.009_bib1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.07.009_bib2","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.07.009_bib3","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.07.009_bib4","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1200\/JCO.23.01055","article-title":"Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO living guideline, version 2023.2","volume":"41","author":"Owen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2024.07.009_bib6","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.07.009_bib7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/03007995.2018.1541443","article-title":"Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls","volume":"35","author":"Li","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtho.2024.07.009_bib8","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.07.009_bib9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.21037\/tlcr-22-656","article-title":"Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer-a narrative review","volume":"12","author":"Chazan","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2024.07.009_bib10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2021.06.012","article-title":"Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC","volume":"158","author":"Zhang","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.07.009_bib11","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/1878-0261.13446","article-title":"EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries","volume":"17","author":"Elshatlawy","year":"2023","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/path.4950","article-title":"Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer","volume":"243","author":"Noh","year":"2017","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jtho.2024.07.009_bib13","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1002\/ijc.31275","article-title":"EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer","volume":"142","author":"Christopoulos","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2024.07.009_bib14","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib15","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the\u00a0global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib16","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jtho.2023.08.010","article-title":"Brigatinib versus Alectinib in ALK-positive NSCLC after disease progression on crizotinib: results of Phase 3 ALTA-3 trial","volume":"18","author":"Yang","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12885-020-06805-5","article-title":"Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis","volume":"20","author":"Qin","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2024.07.009_bib18","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100333","article-title":"Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer","volume":"7","author":"Wolf","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2024.07.009_bib20","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jtho.2023.07.023","article-title":"Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced NSCLC in relation to EML4::ALK variant type and ALK with or without TP53 mutations","volume":"18","author":"Bearz","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib21","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.3390\/curroncol29070382","article-title":"Real-world clinical outcomes after genomic profiling of circulating tumor DNA in patients with previously treated advanced non-small cell lung cancer","volume":"29","author":"Olsen","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib22","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.07.009_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140712","article-title":"Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA","volume":"10","author":"Lanman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2024.07.009_bib24","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1177\/10781552221126174","article-title":"Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors","volume":"29","author":"Wu","year":"2023","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.jtho.2024.07.009_bib25","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/oncolo\/oyac116","article-title":"Real-world efficacy and tolerability of brigatinib in patients with non-small cell lung cancer with prior ALK-TKIs in the United States","volume":"27","author":"Jahanzeb","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2024.07.009_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jtho.2023.08.007","article-title":"Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged NSCLC","volume":"19","author":"Lara-Mej\u00eda","year":"2024","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ijc.31893","article-title":"Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma","volume":"144","author":"Christopoulos","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2024.07.009_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100337","article-title":"Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients","volume":"7","author":"Hua","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2024.07.009_bib29","doi-asserted-by":"crossref","first-page":"S1295","DOI":"10.1016\/j.annonc.2023.10.051","article-title":"LBA2 ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell\u00a0lung cancer (NSCLC)","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib30","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.jtho.2021.01.1612","article-title":"Combination of chemotherapy and ALK inhibitors in ALK-positive NSCLC","volume":"16","author":"De Carlo","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib31","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1200\/JCO.2022.40.16_suppl.9074","article-title":"A\u00a0phase II study of alectinib in combination with bevacizumab as first-line treatment in advanced NSCLC with confirmed ALK fusion: ALEK-B trial","volume":"40","author":"Arrieta","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2023.09.109","article-title":"OA22.04 BRIGHTSTAR local consolidative therapy with brigatinib in tyrosine kinase inhibitor-Na\u00efve ALK-rearranged metastatic NSCLC","volume":"18","author":"Elamin","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib33","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.07.009_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib35","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib36","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib37","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib38","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.18632\/oncotarget.13741","article-title":"Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer","volume":"8","author":"Cui","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2024.07.009_bib39","article-title":"Concordance between tissue ALK detection by immunohistochemistry and plasma ALK detection by next-generation sequencing in the randomized phase 3 ALEX study in patients with treatment-naive advanced ALK-positive NSCLC","volume":"3","author":"No\u00e9","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2024.07.009_bib40","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1158\/1078-0432.CCR-21-2840","article-title":"Circulating cell-free DNA as a prognostic biomarker in patients with advanced ALK+ non-small cell lung cancer in the global phase III ALEX trial","volume":"28","author":"Dziadziuszko","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.07.009_bib41","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jtho.2023.05.021","article-title":"Early circulating tumor DNA dynamics and efficacy of lorlatinib in patients with treatment-naive, advanced, ALK-positive NSCLC","volume":"18","author":"Soo","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jmoldx.2022.02.002","article-title":"Driver mutation variant allele frequency in circulating tumor DNA and association with clinical outcome in patients with non-small cell lung cancer and EGFR- and KRAS-mutated tumors","volume":"24","author":"Li","year":"2022","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.jtho.2024.07.009_bib43","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1200\/PO.20.00532","article-title":"Clinical outcomes in non-small-cell lung cancer patients treated with EGFR-tyrosine kinase inhibitors and other targeted therapies based on tumor versus plasma genomic profiling","volume":"5","author":"Tran","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2024.07.009_bib44","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jtho.2020.12.011","article-title":"Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC","volume":"16","author":"Lam","year":"2021","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424006774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424006774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T02:26:19Z","timestamp":1730773579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086424006774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1556086424006774"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.07.009","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}